Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Australian & New Zealand Journal of PsychiatryOpen Access

Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics – An evidence-based overview for decision makers

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTrang T. T. TruongDeakin UniversityJLJuliana LagoUniversidad de Los AndesJNJennifer Neil

Discussion

Loading...

Member takes

Implication

Perspective article highlights medication selection and health economics in psychotropic pharmacogenetics, suggesting adoption may improve outcomes.

Key Points

  • Psychotropic pharmacogenetics can reduce adverse drug reactions, improving patient care significantly.
  • Clinical evidence shows PGx-guided medication selection can enhance medication efficacy and cut costs.
  • Implementation barriers such as knowledge gaps and funding limits the broader use of PGx in Australia.
  • Emerging combinatorial approaches in pharmacogenetics may shape future psychiatric treatment strategies.

Cite This Study

Truong et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b0e2https://doi.org/10.1177/00048674251369625
View Full Paper
Ask AI
Bookmark
Share